Literature DB >> 20630894

Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.

Carmela Pinnetti, Silvia Baroncelli, Paola Villani, Massimo Fantoni, Valerio Tozzi, Andrea De Luca, Roberto Cauda, Gianfranco Anzidei, Maria Cusato, Mario Regazzi, Marco Floridia, Enrica Tamburrini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20630894     DOI： 10.1093/jac/dkq264

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  11 in total

1.  Pharmacokinetic and safety of raltegravir in pregnancy.

Authors:  Leonardo Croci; Michele Trezzi; Maria Pia Allegri; Tiziana Carli; Silvia Chigiotti; Maria Piera Riccardi; Barbara Ricciardi; Mario Toti; Cesira Nencioni
Journal:  Eur J Clin Pharmacol       Date:  2012-03-01       Impact factor: 2.953

2.  Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.

Authors:  Lisa Rahangdale; Jordan Cates; JoNell Potter; Martina L Badell; Dominika Seidman; Emilly S Miller; Jenell S Coleman; Gweneth B Lazenby; Judy Levison; William R Short; Sigal Yawetz; Andrea Ciaranello; Elizabeth Livingston; Lunthita Duthely; Bassam H Rimawi; Jean R Anderson; Elizabeth M Stringer
Journal:  Am J Obstet Gynecol       Date:  2016-03       Impact factor: 8.661

3.  Raltegravir pharmacokinetics during pregnancy.

Authors:  D Heather Watts; Alice Stek; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Tim R Cressey; Francesca Aweeka; Patty Lizak; Regis Kreitchmann; Sandra K Burchett; David E Shapiro; Elizabeth Hawkins; Elizabeth Smith; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-01       Impact factor: 3.731

4.  Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women.

Authors:  Isabella Nóbrega; Ana Gabriela Travassos; Tatiana Haguihara; Fábio Amorim; Carlos Brites
Journal:  AIDS Res Hum Retroviruses       Date:  2013-06-25       Impact factor: 2.205

5.  Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.

Authors:  Cécile Vinot; Jean-Marc Tréluyer; Carole Giraud; Laurent Gavard; Gilles Peytavin; Laurent Mandelbrot
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 6.  Pharmacokinetic optimization of antiretroviral therapy in pregnancy.

Authors:  Kajal Buckoreelall; Tim R Cressey; Jennifer R King
Journal:  Clin Pharmacokinet       Date:  2012-10-01       Impact factor: 5.577

Review 7.  Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics.

Authors:  Kajal B Larson; Jennifer R King; Edward P Acosta
Journal:  Adolesc Health Med Ther       Date:  2013-08-27

8.  Thai national guidelines for the prevention of mother-to-child transmission of human immunodeficiency virus 2017.

Authors:  Rangsima Lolekha; Kulkanya Chokephaibulkit; Nittaya Phanuphak; Surasith Chaithongwongwatthana; Sasisopin Kiertiburanakul; Pleonchan Chetchotisakd; Sarawut Boonsuk
Journal:  Asian Biomed (Res Rev News)       Date:  2017-04

9.  A case series of third-trimester raltegravir initiation: Impact on maternal HIV-1 viral load and obstetrical outcomes.

Authors:  I Boucoiran; K Tulloch; N Pick; F Kakkar; J van Schalkwyk; D Money; M Boucher
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 May-Jun       Impact factor: 2.471

10.  Micronucleated erythrocytes in newborn rats exposed to raltegravir placental transfer.

Authors:  Blanca Miriam Torres-Mendoza; Damharis Elizabeth Coronado-Medina; Belinda Claudia Gómez-Meda; Eduardo Vázquez-Valls; Ana Lourdes Zamora-Perez; María de Lourdes Lemus-Varela; Guillermo Moisés Zúñiga-González
Journal:  Biomed Res Int       Date:  2014-05-25       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.